PTC Therapeutics, Inc. (NASDAQ:PTCT) Receives $33.53 Average PT from Brokerages

PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Free Report) has received a consensus recommendation of “Reduce” from the thirteen analysts that are currently covering the firm, Marketbeat reports. Five analysts have rated the stock with a sell rating, five have assigned a hold rating and three have assigned a buy rating to the company. The average […]

Related Keywords

United States ,Canada ,China ,Allan Steven Jacobson ,Hexagon Capital Partners ,Wells Fargo Company ,Cantor Fitzgerald ,Lazard Asset Management ,Securities Exchange Commission ,Morgan Stanley ,Nisa Investment Advisors ,China Universal Asset Management Co ,Nasdaq ,Therapeutics Company Profile ,Royal Bank ,Ptc Therapeutics Inc ,Therapeutics Inc ,Get Free Report ,Stock Down ,Director Allan Steven Jacobson ,Exchange Commission ,Marie Utter ,Capital Partners ,Universal Asset Management ,Asset Management ,Investment Advisors ,Get Free ,Ptc Therapeutics ,Nasdaq Ptct ,Ptct ,Medical ,Ratings ,Consensus ,